[go: up one dir, main page]

WO1996035713A1 - Dipeptides stimulant la liberation de l'hormone de croissance - Google Patents

Dipeptides stimulant la liberation de l'hormone de croissance Download PDF

Info

Publication number
WO1996035713A1
WO1996035713A1 PCT/IB1995/000333 IB9500333W WO9635713A1 WO 1996035713 A1 WO1996035713 A1 WO 1996035713A1 IB 9500333 W IB9500333 W IB 9500333W WO 9635713 A1 WO9635713 A1 WO 9635713A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
alkyl
oxo
phenyl
amino
Prior art date
Application number
PCT/IB1995/000333
Other languages
English (en)
Inventor
Philip A. Carpino
Paul A. Dasilva Jardine
Bruce A. Lefker
John A. Ragan
Original Assignee
Pfizer, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Inc. filed Critical Pfizer, Inc.
Priority to PCT/IB1995/000333 priority Critical patent/WO1996035713A1/fr
Priority to CA002220055A priority patent/CA2220055C/fr
Priority claimed from CA002220055A external-priority patent/CA2220055C/fr
Publication of WO1996035713A1 publication Critical patent/WO1996035713A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Definitions

  • Dipeptides which Promote Release of Growth Hormone This invention relates to dipeptide compounds which are growth hormone releasing peptide (GHRP) mimetics and are useful for the treatment and prevention of osteoporosis.
  • GHRP growth hormone releasing peptide
  • Growth hormone which is secreted from the pituitary, stimulates growth of all tissues of the body that are capable of growing.
  • growth hormone is known to have the following basic effects on the metabolic process of the body: 1. Increased rate of protein synthesis in all cells of the body;
  • a deficiency in growth hormone secretion can result in various medical disorders, such as dwarfism.
  • chemicals such as arginine, L-3,4-dihydroxyphenylalanine (L-DOPA), glucagon, vasopressin, and insulin induced hypoglycemia, as well as activities such as sleep and exercise, indirectly cause growth hormone to be released from the pituitary by acting in some fashion on the hypothalamus perhaps either to decrease somatostatin secretion or to increase the secretion of the known secretagogue growth hormone releasing factor (GRF) or an unknown endogenous growth hormone-releasing hormone or all of these.
  • L-DOPA L-3,4-dihydroxyphenylalanine
  • GRF growth hormone releasing factor
  • the problem was generally solved by providing exogenous growth hormone or by administering an agent which stimulated growth hormone production and/or release.
  • an agent which stimulated growth hormone production and/or release In either case the peptidyl nature of the compound necessitated that it be administered by injection.
  • the source of growth hormone was the extraction of the pituitary glands of cadavers. This resulted in a very expensive product and carried with it the risk that a disease associated with the source of the pituitary gland could be transmitted to the recipient of the growth hormone.
  • Recently, recombinant growth hormone has become available which, while no longer carrying any risk of disease transmission, is still a very expensive product which must be given by injection or by a nasal spray.
  • WO 94/13696 refers to certain spiropiperidines and homologs which promote release of growth hormone. Preferred compounds are of the general structure shown below.
  • WO 94/11012 refers to certain dipeptides that promote release of growth hormone. These dipeptides have the general structure
  • the compounds of WO 94/11012 and WO 94/13696 are reported to be useful in the treatment of osteoporosis in combination with parathyroid hormone or a bisphosphonate.
  • This invention provides a compound of the formula:
  • L is NR 6 , O or CH2;
  • W is hydrogen or in combination with X is a benzo fusion in which W and X are linked to form a phenyl ring optionally substituted with one to three substituents independently selected from R 3a , T-R 3b and R 12 ;
  • Y is hydrogen, C1-C6 alkyl, C4-C10 cycloalkyl or aryl, each optionally substituted with one to three substituents selected from R , R 3b and R ,
  • X is OR 2 ,
  • R 2c is hydrogen, C -C6 alkyl, C3-C7 cycloalkyl, and may be joined with R 1 to form a C3-C8 ring optionally including oxygen, sulfur or NR 2a ;
  • R 2 is hydrogen, C -C6 alkyl, C3-C7 cycloalkyl
  • R 2a is hydrogen or C1 -C6 alkyl
  • R 2b is hydrogen C1-C8 alkyl, C1-C8 halogenated alkyl, C3-C8 cycloalkyl, alkylaryl or aryl;
  • R3a is H, F, Cl, Br, I, CH3, OCH3 or CF3;
  • R 1 is H, F, Cl, Br, I, CH3, OCH3 or CF3;
  • T is a bond or is phenyl or a 5 or 6-membered heterocycle containing 1 to 3 hetero atoms selected from nitrogen, sulfur or oxygen, each optionally substituted with one to three substituents selected from F, Cl, Br, I, CH3, OCH3, OCF3 and CF3;
  • R 3 is hydrogen, CONR8R9, S02NR 8 R 9 , COOH, COO(C ⁇ -C6)alkyl, NR 2 S ⁇ 2R 9 , NR CONR8R9, NR2S02NR8R 9 , I R2C(0)R9, imidazolyl, thiazolyl or tetrazolyl;
  • R 4 and R 5 are independently hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl where the substituents may be 1 to 5 halo, 1 to 3 hydroxy, 1 to 3 C1-C10 alkanoyloxy, 1 to 3 C1-C6 alkoxy, phenyl, phenoxy, 2-furyl, C1-C6 alkoxycarbonyl, S(0) m (C ⁇ -C6 alkyl); or R 4 and R 5 can be taken together to form -(CH2)r a(CH2)s- where L a is C(R )2, O, S(0)m or N(R 2 ), r and s are independently 1 to 3 and R 2 is as defined above;
  • R 6 is hydrogen or C1-C6 alkyl, and may be joined with R 2 c to form a C3- C8 ring;
  • M is -C(O)- or -SO2-;
  • a 1 is a bond, C1-C6 alkylene, C1-C6 haloalkylenyl or C1-C6 hydroxyalkylenyl;
  • A is a bond or is
  • Z 1 is N-R 2 or O; or Z 1 is a bond;
  • R 7 and R 7a are independently hydrogen, C1-C6 alkyl, trifluoromethyl, phenyl, substituted C-J-C6 alkyl where the substituents are imidazolyl, phenyl, indolyl, p-hydroxyphenyl, OR 2 , S(0) m R 2 , C(0)OR 2 , C3-C7 cycloalkyl, N(R 2 )(R 2 ), C(0)N(R 2 )(R 2 ); or R 7 and R 7a can independently be joined to one or both of R 4 and R 5 groups to form alkylene bridges between the terminal nitrogen and the alkyl portion of the R 7 and R 7a groups, wherein the bridge contains 1 to 5 carbon atoms; or R 7 and R 7a may be joined to form a 3- to 7- membered ring.
  • R 9 is hydrogen, C1-C6 alkyl, phenyl, thiazolyl, imidazolyl, furyl or thienyl each optionally substituted with one to three substituents selected from Cl, F, CH3, OCH3, OCF 3 and CF3;
  • R8 is hydrogen, C-i-C ⁇ alkyl, substituted C1-C6 alkyl where the substituents may be 1 to 5 halo, 1 to 3 hydroxy, 1 to 3 C1-C10 alkanoyloxy, 1 to 3 C1-C6 alkoxy, phenyl, phenoxy, C1-C6 alkoxycarbonyl, S(0)m(C ⁇ -C6 alkyl); or R 8 and R 9 can be taken together to form -(CH2)rL-a(CH2)s- where L a is C(R 2 )2, O, S(0)m or N(R ), r and s are independently 1 to 3.
  • F 1 , B, D and E are carbon, nitrogen, one of which is joined to A 1 and each of the remaining of F 1 , B, D and E may be optionally substituted with R aa , R DD ; or F 1 , B, D and E, if not joined to A 1 may also be sulfur, oxygen or carbonyl; F 1 , B, D and E may form a saturated or unsaturated ring; and one of F 1 , B, D or E may be optionally missing to afford a saturated or unsaturated five-membered ring; R aa is H, C1-C8 alkyl optionally substituted with one to three halogens; or phenyl optionally substituted with one to three substituents independently selected from halogen, CH3, OCH3, OCF3, CF3 and C1-C8 alkyl aryl;
  • R DD is C1-C8 alkyl, C1-C8 alkoxy, C1-C8 thioalkyl, each optionally substituted with one to three substituents independently selected from halogen, CH3, OCH3, OCF3, CF3; C3-C8 cycloalkyl; phenyl optionally substituted with one to three substituents independently selected from halo, CH3, OCH3, OCF3 or CF3; -O-C1-C8 alkyl; or -S-C1-C8 alkyl.
  • G, H 1 , 1 and J are carbon, nitrogen, sulfur or oxygen atoms which form an aromatic ring, a partially saturated ring or a saturated ring; one of G, H 1 , 1 or J may be optionally missing to afford a five-membered ring; aryl is phenyl, naphthyl or a 5- or 6- membered ring with 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen; or a bicyclic ring system consisting of a 5 or 6 membered heterocyclic ring with 1 to 3 heteroatoms of nitrogen, sulfur or oxygen, fused to a phenyl ring, each aryl ring being optionally and independently substituted with up to three substituents selected from R 3a , R 3b and R 2 ; m is 0 to 2; n is 0 to 2; q is 0 to 3; and pharmaceutically acceptable salts and individual diastereomers thereof.
  • this invention provides a compound of Formula I wherein Z is -COCR 1 R2CNHCOANR4R5 A is -CR R 7a (CH2) ⁇ ; Y is 0 to 3; and R2c J S H or CH3;
  • R 7 is C1-C3 alkyl
  • R a is H or C ⁇ -C3 alkyl
  • R 4 is hydrogen or C1-C3 alkyl; or R 4 and R 7a are combined to form an alkylene bridge;
  • R 5 is hydrogen or C1-C3 alkyl optionally substituted with one or two hydroxyl groups.
  • this invention provides a compound of Formula I wherein R 1 is selected from the group consisting of 1-indolyl-CH2-; 2-indolyl-
  • this invention provides a compound of Formula I wherein R 1 is C6H5CH2OCH2-, 1-naphthyl-CH2-, 2-naphthyl-CH2-, phenylpropyl or
  • this invention provides a compound of Formula I which is:
  • R 3a is H, F, Cl, Br, I, CH3, OCH3 or CF3;
  • R12 is H, F, Cl, Br, I, CH3, OCH3 or CF3;
  • T is a bond or is an aryl group selected from phenyl, pyridyl, pyrimidyl, thienyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl and tetrazolyl; each optionally substituted with one to three F, CH3, Cl, OR 8 , OCH3, OCF3 or CF3;
  • R 3b is hydrogen, CONR 8 R 9 , S ⁇ 2NR 8 R 9 , COOH, COO(C-
  • R 9 is hydrogen, C1-C6 alkyl, phenyl, thiazolyl, imidazolyl, furyl or thienyl each optionally substituted with one to three substituents selected from Cl, F, CH3, OCH3, OCF3 and CF3;
  • R 8 is hydrogen, C -C6 alkyl, C3-C7 cycloalkyl, substituted C1-C6 alkyl where the substituents may be 1 to 5 halo, 1 to 3 hydroxy, 1 to 3 C1-C10 alkanoyloxy, 1 to 3 C1-C6 alkoxy, phenyl, phenoxy, C1-C6 alkoxycarbonyl, S(0)2(C ⁇ -C6 alkyl); or R 8 and R 9 can be taken together to form -(CH2)rL a (CH2)s- where L a is C(R2) 2( O, S(0)2 or N(R 2 ), r and s are independently 1 to 3. in another aspect, this invention provides a compound of Formula II wherein: m is one;
  • R 12 is hydrogen
  • R 3a is hydrogen, F or Cl;
  • T is phenyl, thienyl, thiazolyl, oxazolyl, isoxazolyl or pyrazolyl, each optionally substituted with one to three substituents, selected from F, OH, OCH3, OCF3, CF3 and CH3;
  • R 3b is hydrogen, C(0)NR 8 R 9 , NHC(0)NR 8 R 9 , NHS(0)2R 9 , NHC(0)R 9 ;
  • this invention provides a compound of Formula II wherein: m is one;
  • R 3a and R 12 are hydrogen.
  • R 3b is CONR 8 R 9 , S ⁇ 2NR 8 R 9 , COOH, COO(C ⁇ -C6)alkyl, NHSO2R 9 ,
  • R 9 is hydrogen, phenyl, or thienyl optionally substituted with one to three substituents selected from F, CH3, OCH3, OCF3 and CF3; or R 9 is C1-C6 alkyl optionally substituted with one to three substituents selected from F, OH, OCH3, OCF3 and CF3; or R 8 ;
  • R 8 is hydrogen, C1-C6 alkyl, optionally substituted C1-C6 alkyl or C3- C7 cycloalkyl where the substituents may be 1 to 5 halo or 1 to 3 hydroxy; or R 8 and R 9 can be taken together to form -(CH2)rLa(CH2)s- wherein La is C(R 2 )2, O, S(0)m or N(R 2 ) where r and s are independently 1 to 3.
  • this invention provides a compound of Formula I n is one; m is one;
  • W is hydrogen; Y is hydrogen or methyl;
  • M is -C(O)- ;
  • R50 is 4-morpholino, 4-(1-methylpiperazinyl), C3-C7 cycloalkyl or C1- C ⁇ alkyl each optionally substituted with one to three substituents individually selected from F, OH, OCH3, OCF3 and CF3;
  • Ar is phenyl, pyridyl, thienyl, pyrimidyl or thiazolyl, each optionally substituted with one to three substituents individually selected from F, Cl, CH3, OCH3, OCF3 and CF3.
  • this invention provides a compound of Formula I wherein n and m are one; Y is phenyl, pyridyl, pyrimidyl, thienyl, or thiazolyl, each optionally substituted with one to three substituents independently selected from F, Cl, CH3, OCH3, OCF3 and CF3; X is -C(0)-NR 8 R 9 ;
  • R 9 is hydrogen, C1-C6 alkyl, phenyl, thiazolyl, imidazolyl, furyl or thienyl each optionally substituted with one to three substituents selected from Cl, F, CH3, OCH3, OCF3 and CF3;
  • R 8 is hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl where the substituents may be 1 to 5 halo, 1 to 3 hydroxy, 1 to 3 C1-C10 alkanoyloxy, 1 to 3 C1-C6 alkoxy, phenyl, phenoxy, C1-C6 alkoxycarbonyl, S(0)m(C ⁇ -C6 alkyl); or R 8 and R 9 can be taken together to form -(CH2)rLa(CH2)s- where L a is C(R )2, O, S(0)m or N(R 2 ), r and s are independently 1 to 3.
  • this invention provides a compound of Formula I wherein
  • Z is -COCR 1
  • R2CNHCOANR4R5 A is -CR R a (CH2) ⁇
  • Y is 0 to 3
  • R2c j s H or CH3;
  • R 7 is C1-C3 alkyl
  • R is H or C ⁇ -C3 alkyl
  • R 4 is hydrogen or C1 -C3 alkyl; or R 4 and R 7a are combined to form an alkylene bridge;
  • R 5 is hydrogen or C1 -C3 alkyl optionally substituted with one or two hydroxyl groups;
  • R 1 is selected from the group consisting of 1-indolyl-CH2-; 2-indolyl- CH2-; 3-indolyl-CH2-; 1-naphthyl-CH2-; 2-naphthyl-CH2-; 1 -benzimidazolyl- CH2-; 2-benzimidazolyl-CH2-; phenyl-C ⁇ -C4 alkyl-; 2-, 3- or 4-pyridyl-C ⁇ -C4 alkyl; thienyl-Ci -C4 alkyl; phenyl-(CH2)n-0-CH2- where n is zero to three; phenyl-CH2 ⁇ -phenyl-CH2-; and 3-benzothienyl-CH2-; or any of the above groups substituted in the aryl portion with one to three F, Cl, CH3, OCH3, OCF3 or CF3 substituents
  • Y is hydrogen and X is:
  • n and m are one and A 1 is a bond, or X is:
  • R 3a is hydrogen, F, Cl, CH3, OCH3, OCF3 or CF3;
  • R 12 is hydrogen, F, Cl, CH3, OCH3, OCF3 or CF3;
  • R aa is hydrogen, C1-C8 alkyl optionally substituted with one to three halogens; or phenyl optionally substituted with one to three substituents independently selected from halogen, CH3, OCH3, OCF3, CF3 and C1-C8 alkyl aryl;
  • R bb is hydrogen, Ci-C ⁇ alkyl, optionally substituted with one to three substituents independently selected from halogen, CH3, OCH3, OCF3.
  • CF3 C3-C8 cycloalkyl
  • phenyl optionally substituted with one to three substituents independently selected from halo, CH3, OCH3, OCF3 or CF3; -O-C1-C8 alkyl; or -S-C1-C8 alkyl.
  • this invention provides a compound of Formula I wherein Z is
  • n is independently zero or one
  • R1 is 1-naphthyl CH2-, 2-naphthyl CH2, phenyl CH2CH2CH2-
  • Preferred compounds of Formula I are:
  • This invention further provides a method for treating or preventing diseases or conditions which may be treated or prevented by growth hormone which comprises administering to a mammal in need of such treatment or prevention an amount of a compound of Formula I which is effective in promoting release of said growth hormone.
  • this invention provides compositions and methods which are useful for treating obesity, fraility associated with old age, and cachexia associated with AIDS and cancer.
  • the instant compounds are highly substituted dipeptide analogs for promoting the release of growth hormone which are stable under various physiological conditions which may be administered parenterally, nasally or by the oral route.
  • the compounds of Formula I can be made by processes which include processes known in the chemical arts for the production of structurally analogous compounds. Certain processes for the manufacture of Formula I compounds are provided as further features of the invention and are illustrated by the following reaction schemes.
  • alkyl groups specified above are intended to include those alkyl groups of the designated length in either a straight or branched configuration which may optionally contain double or triple bonds.
  • alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl, allyl, ethinyl, propenyl, butadienyl, hexenyl and the like.
  • the alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a straight or branched configuration which may optionally contain double or triple bonds.
  • alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy, allyloxy, 2-propinyloxy, isobutenyloxy, hexenyloxy and the like.
  • halogen or halo is intended to include the halogen atoms fluorine, chlorine, bromine and iodine.
  • aryl is intended to include phenyl and naphthyl and aromatic
  • heterocyclic aromatic rings are pyridine, thiophene, furan, benzothiophene, tetrazole, indole, N-methylindole, dihydroindole, indazole, N- formylindole, benzimidazole, thiazole, pyrimidine, and thiadiazole.
  • the compounds of the instant invention all have at least one asymmetric center as noted by the asterisk in the structural Formula I, group Z above. Additional asymmetric centers may be present on the molecule depending upon the nature of the various substituents on the molecule. Each such asymmetric center will produce two optical isomers and it is intended that all such optical isomers, as separated, pure or partially purified optical isomers, racemic mixtures or diastereomeric mixtures thereof, be included within the ambit of the instant invention.
  • the asymmetric center represented by the asterisk it has been found that the absolute stereochemistry of the more active and thus more preferred isomer is shown in Formula IA. This preferred absolute configuration also applies to Formula I.
  • the spatial configuration of the asymmetric center corresponds to that in a D-amino acid. In most cases this is also designated an E- configuration although this will vary according to the values of Ri and R2 used in making E- or S-stereochemical assignments.
  • the instant compounds are generally isolated in the form of their pharmaceutically acceptable acid addition salts, such as the salts derived from using inorganic and organic acids.
  • acids are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, malonic, methane sulfonic and the like.
  • certain compounds containing an acidic function such as a carboxy can be isolated in the form of their inorganic salt in which the counterion can be selected from sodium, potassium, lithium, calcium, magnesium and the like, as well as from organic bases.
  • the growth hormone releasing compounds of Formula I are useful in vitro as unique tools for understanding how growth hormone secretion is regulated at the pituitary level. This includes use in the evaluation of many factors thought or known to influence growth hormone secretion such as age, sex, nutritional factors, glucose, amino acids, fatty acids, as well as fasting and non-fasting states. In addition, the compounds of this invention can be used in the evaluation of how other hormones modify growth hormone releasing activity. For example, it has already been established that somatostatin inhibits growth hormone release.
  • hormones that are important and in need of study as to their effect on growth hormone release include the gonadal hormones, e.g., testosterone, estradiol, and progesterone; the adrenal hormones, e.g., cortisol and other corticoids, epinephrine and norepinephrine; the pancreatic and gastrointestinal hormones, e.g., insulin, glucagon, gastrin, secretin; the vasoactive peptides, e.g., bombesin, the neurokinins; and the thyroid hormones, e.g., thyroxine and triiodothyronine.
  • gonadal hormones e.g., testosterone, estradiol, and progesterone
  • the adrenal hormones e.g., cortisol and other corticoids, epinephrine and norepinephrine
  • the pancreatic and gastrointestinal hormones e.g., insulin, glucagon,
  • the compounds of Formula I can also be employed to investigate the possible negative or positive feedback effects of some of the pituitary hormones, e.g., growth hormone and endorphin peptides, on the pituitary to modify growth hormone release.
  • some of the pituitary hormones e.g., growth hormone and endorphin peptides
  • endorphin peptides e.g., endorphin peptides
  • the compounds of Formula I can be administered to animals, including man, to release growth hormone in vivo.
  • the compounds can be administered to commercially important animals such as swine, cattle, sheep and the like to accelerate and increase their rate and extent of growth, to improve feed efficiency and to increase milk production in such animals.
  • these compounds can be administered to humans in vivo as a diagnostic tool to directly determine whether the pituitary is capable of releasing growth hormone.
  • the compounds of Formula I can be administered in vivo to children. Serum samples taken before and after such administration can be assayed for growth hormone. Comparison of the amounts of growth hormone in each of these samples would be a means for directly determining the ability of the patient's pituitary to release growth hormone.
  • the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of Formula I in association with a pharmaceutical by acceptable carrier.
  • the active ingredient of the pharmaceutical compositions can comprise an anabolic agent in addition to at least one of the compounds of Formula I or another composition which exhibits a different activity, e.g., an antibiotic growth permittant or an agent to treat osteoporosis or in combination with a corticosteroid to minimize the catabolic side effects or with other pharmaceutically active materials wherein the combination enhances efficacy and minimizes side effects.
  • Growth promoting and anabolic agents include, but are not limited to, TRH, PTH, diethylstilbesterol, estrogens, ⁇ -agonists, theophylline, anabolic steroids, enkephaiins, E series prostaglandins, compounds disclosed in U.S. Patent No. 3,239,345, e.g., zeranol, and compounds disclosed in U.S. Patent No. 4,036,979, e.g., sulbenox or peptides disclosed in U.S. Patent No. 4,411 ,890.
  • a still further use of the growth hormone secretagogues of this invention is in combination with other growth hormone secretagogues such as the growth hormone releasing peptides GHRP-6, GHRP-1 as described in U.S. Patent Nos. 4,411 ,890 and publications WO 89/07110, WO 89/07111 and B- HT920 as well as hexarelin and the newly discovered GHRP-2 as described in WO 93/04081 or growth hormone releasing hormone (GHRH, also designated GRF) and its analogs or growth hormone and its analogs or somatomedins including IGF-1 and IGF-2 or ⁇ -adrenergic agonists such as clonidine or serotonin 5HTID agonists such as sumitriptan or agents which inhibit somatostatin or its release such as physostigmine and pyridostigmine.
  • growth hormone secretagogues such as the growth hormone releasing peptides GHRP-6, GHRP-1 as described in U.S
  • growth hormone may be summarized as follows: stimulating growth hormone release in elderly humans; treating growth hormone deficient adults; prevention of catabolic side effects of glucocorticoids, treatment of osteoporosis, stimulation of the immune system, acceleration of wound healing, accelerating bone fracture repair, treatment of growth retardation, treating acute or chronic renal failure or insufficiency, treatment of physiological short stature, including growth hormone deficient children, treating short stature associated with chronic illness, treatment of obesity, treating growth retardation associated with Prader-Willi syndrome and Turner's syndrome; accelerating the recovery and reducing hospitalization of burn patients or following major surgery such as gastrointestinal surgery; treatment of intrauterine growth retardation, skeletal dysplasia, hypercortisonism and Cushings syndrome; replacement of growth hormone in stressed patients; treatment of osteochondrodysplasias, Noonans syndrome, sleep disorders, Alzheimer's disease, delayed wound healing, and psychosocial deprivation; treatment of pulmonary dysfunction and ventilator dependency; attenuation of protein catabolic response after a major operation;
  • the therapeutic agents and the growth hormone secretagogues of this invention may be independently present in dose ranges from one one- hundredth to one times the dose levels which are effective when these compounds and secretagogues are used singly.
  • Combined therapy to inhibit bone resorption, prevent osteoporosis and enhance the healing of bone fractures can be illustrated by combinations of bisphosphonates and the growth hormone secretagogues of this invention.
  • the use of bisphosphonates for these utilities has been reviewed, for example, by Hamdy, N.A.T., Role of Bisphosphonates in Metabolic Bone Diseases. Trends in Endoc ⁇ nol. Metab., 1993. 4, 19-25.
  • Bisphosphonates with these utilities include alendronate, tiludronate, dimethyl - APD, risedronate, etidronate, YM-175, clodronate, pamidronate, and BM-210995.
  • oral daily dosage levels of the bisphosphonate of between 0.1 mg and 5 g and daily dosage levels of the growth hormone secretagogues of this invention of between 0.01 mg/kg to 20 mg/kg of body weight are administered to patients to obtain effective treatment of osteoporosis.
  • Compounds that have the ability to stimulate GH secretion from cultured rat pituitary cells are identified using the following protocol. This test is also useful for comparison to standards to determine dosage levels.
  • Cells are isolated from anterior pituitaries of 6-week old male Wistar rats following decapitation. Tissues are finely minced, then subjected to mechanical and enzymatic dispersion using 10 U/mL bacterial protease (EC 3.4.24.4, Sigma P- 6141) in Hank's balanced salt solution without calcium or magnesium.
  • the cell suspension is plated at 5x10 4 cells per square cm in 24-well Costar dishes and cultured for 3 days in Dulbecco's Modified Eagles Medium (D-MEM) supplemented with 4.5 g/L glucose, 10% horse serum, 2.5% fetal bovine serum, non-essential amino acids, 100 U/mL nystatin and 50 mg/mL gentamycin sulfate.
  • D-MEM Dulbecco's Modified Eagles Medium
  • culture wells are rinsed twice, then equilibrated for 30 minutes in release medium (D-MEM buffered with 25 mM Hepes, pH 7.4 and containing 0.5% bovine serum albumin at 37°C.
  • Test compounds are dissolved in DMSO, then diluted into pre-warmed release medium.
  • the assay is initiated by adding 1 mL of release medium (with test compounds) to each culture well. Incubation is carried out at 37°C for 15 minutes, then terminated by removal of the culture medium, which is centrifuged at 2000 x g for 15 minutes to remove cellular material before being assayed for rat growth hormone by a radioimmunoassay procedure using reagents provided by A.F.
  • Nonpeptidyl GH secretogogues are shown to mimic growth hormone releasing peptides based on one or more of the following criteria: synergistic stimulation of GH release when added together with GHRH, inability to further increase GH secretion by GHRP-6, sensitivity to protein kinase C inhibitors, and selective stimulation of biphasic calcium flux in GH-containing cells.
  • the compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual, or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
  • parenteral e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant
  • nasal, vaginal, rectal, sublingual, or topical routes of administration can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch.
  • Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate.
  • the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
  • Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions.
  • non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.
  • Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria- retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax.
  • compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
  • the dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained.
  • the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. Generally, dosage levels of between 0.0001 to 100 mg/kg of body weight daily are administered to patients and animals, e.g., mammals, to obtain effective release of growth hormone. A preferred dosage range is 0.01 to 5.0 mg/kg of body weight daily.
  • the preparation of the compounds of Formula I of the present invention can be carried out in sequential or convergent synthetic routes. Syntheses detailing the preparation of the compounds of Formula I in a sequential manner are presented in the following reaction schemes.
  • protected amino acid derivatives are commercially available, where the protecting groups P are, for example, BOC, CBZ, FMOC, benzyl or ethoxycarbonyl groups.
  • Other protected amino acid derivatives can be prepared by literature methods.
  • Some substituted pyrrolidines, piperidines and tetrahydroisoquinolines are commercially available, and many other pyrrolidines, 4-substituted piperidines, and 1,2,3,4-tetrahydroisoquinolines are known in the literature.
  • Various phenyl or heteroaryl substituted piperidines and 1 ,2,3,4-tetrahydroisoquinolines can be prepared following literature methods using derivatized phenyl and heteroaryl intermediates. Alternatively the phenyl or heteroaryl rings of such compounds can be derivatized by standard means, such as halogenation, nitration, sulfonylation etc.
  • Benzyloxycarbonyl groups can be removed by a number of methods including, catalytic hydrogenation with hydrogen in the presence of a palladium or platinum catalyst in a protic solvent such as methanol.
  • Preferred catalysts are palladium hydroxide on carbon or palladium on carbon. Hydrogen pressures from 1-1000 psi may be employed; pressures from 10 to 70 psi are preferred.
  • the benzyloxycarbonyl group can be removed by transfer hydrogenation.
  • Removal of BOC protecting groups can be carried out using a strong acid such as trifluoroacetic acid or hydrochloric acid with or without the presence of a cosolvent such as dichloromethane or methanol at a temperature of about -30 to 70°C, preferably about -5 to about 35°C.
  • a strong acid such as trifluoroacetic acid or hydrochloric acid
  • a cosolvent such as dichloromethane or methanol
  • Benzyl esters of amines can be removed by a number of methods including, catalytic hydrogenation with hydrogen in the presence of a palladium catalyst in a protic solvent such as methanol. Hydrogen pressures from 1-1000 psi may be employed; pressures from 10 to 70 psi are preferred. The addition and removal of these and other protecting groups is discussed by T. Greene in Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1981.
  • the protected amino acid derivatives 1 are in many cases commercially available, where the protecting group P is, for example, BOC or CBZ groups.
  • Other amino acids can be prepared by literature methods. As illustrated in Scheme 1 , coupling of amines of formula 2 with protected amino acids of formula 1 , where P is a suitable protecting group, is conveniently carried out in an inert solvent such as dichloromethane or DMF by a coupling reagent such as EDC or DCC in the presence of HOBT. In the case where the amine is present as the hydrochloride salt, it is preferable to add one equivalent of a suitable base such as triethylamine to the reaction mixture.
  • a suitable base such as triethylamine
  • the coupling can be effected with a coupling reagent such as BOP in an inert solvent such as methanol.
  • a coupling reagent such as BOP in an inert solvent such as methanol.
  • Such coupling reactions are generally conducted at temperatures of about -30 to about 80°C, preferably 0 to about 25°C.
  • Transformation of 3 into intermediates of formula 4 can be carried out by removal of the protecting group P as described above. Coupling of intermediates of formula 4 to amino acids of formula 5 can be effected as described above to give intermediates of formula 6. Deprotection of the amine 6 gives compounds of formula 7.
  • compounds of formula 7 can be prepared by a convergent route as shown in Scheme 2.
  • Intermediate esters of formula 8 can be prepared by treating amino acids 1 , where P is a suitable protecting group, with a base such as potassium carbonate followed by an alkyl halide such as iodomethane in a suitable solvent such as DMF. Deprotection of the amine transforms 8 into 9. Alternatively, many amino acids of formula 9 are commercially available.
  • Intermediate 10 is generated by coupling 9 to amino acid 5.
  • the ester of intermediate 10 can be converted to intermediate acid 11 by a number of methods known in the art; for example, methyl and ethyl esters can be hydrolyzed with lithium hydroxide in a protic solvent such as aqueous methanol or aqueous THF at a temperature of about -20 to 120°C, preferably about 20 to 70°C.
  • a protic solvent such as aqueous methanol or aqueous THF
  • removal of a benzyl group can be accomplished by a number of reductive methods including hydrogenation in the presence of -30- platinum or palladium catalyst in a protic solvent such as methanol.
  • Acid 11 can then be coupled to amine 2 to give intermediates of formula 6. Transformation of 6 to 7 can be achieved by removal of the protecting group P.
  • compounds of formula 18 can be prepared by treating 2-nitrobenzaldehydes of formula 16 with amines of formula 17 in the presence of a suitable reducing agent which include alkali metal borohydrides and cyanoborohydrides.
  • a suitable reducing agent which include alkali metal borohydrides and cyanoborohydrides.
  • the preferred reducing agent is sodium cyanoborohydride.
  • Sodium borohydride and sodium triacetoxyborohydride may also be used.
  • the nitro group of compound 18 can be reduced by a number of methods including hydrogenation with a catalyst such as palladium in a protic solvent such as methanol to give compounds of formula 19. Cyclization of the diamine with N.N'-carbonyldiimidazole (CDI) or other phosgene equivalents generates compounds of formula 20. Removal of the protecting group transforms 20 into 12.
  • CDI N.N'-carbonyldiimidazole
  • a hydride reducing agent such as sodium borohydride.
  • the nitro group of formula 23 can be reduced by a number of methods including hydrogenation with a catalyst such as palladium in a solvent such as methanolic HCl to give compounds of formula 24.
  • Cyclization with CDI or other phosgene equivalents produces the benzimidazolinones of formula 25. Transformation of 25 into 26 can be achieved by removal of the protecting group P.
  • the benzimidazolinones of formula 26 can also be prepared by treating 2-anthranilic acids of formula 27 with N-protected piperidones of formula 22 in the presence of a hydride reducing agent such as sodium cyanoborohydride to give compounds of formula 28.
  • the acid of formula 28 can then be treated with diphenylphosphoryl azide to give the aroyl azide of formula 29.
  • Heating 29 in xylene produces the benzimidazolinones of formula 30. Transformation of 30 into 26 can be achieved by removal of the protecting group P.
  • a coupling agent such as EDC in the presence of HOBT in an inert solvent such as dichloromethane
  • Subsequent removal of the protecting group generates compounds of formula 37.
  • 33 can be treated with an aryl or alkyl sulfonyl chloride 38 in the presence of an acid scavenger to generate
  • compounds of formula 50 can be prepared by treating a 4-piperidone of formula 22, with equimolar amounts of potassium cyanide and a primary or secondary amine hydrochloride in aqueous ethanol to give intermediates of formula 49. Intermediates of formula 49 can then be deprotected to give compounds of formula 50.
  • the nitrile group of 52 can be reduced by a number of methods (March, J., Advanced Org. Chem.; Reactions, Mechanisms, and Structure, John Wiley & Sons, New York, 1985), including lithium aluminum hydride to give the primary amine of compound 54.
  • Intermediate 54 can then be coupled to acids of formula 35 as outlined in Scheme 12 to give compounds of formula 55.
  • Subsequent deprotection of the piperidine amine gives compounds of formula 56.
  • the nitrile 52 can also be converted to an ester as described in Scheme 13 by heating intermediate 52 with concentrated sulfuric acid and a small amount of water to temperatures around 150°C, followed by heating the mixture in an alcohol solvent to temperatures around 125°C. Deprotection of the piperidine amine 57 generates compounds of formula 58.
  • the nitrile can be hydrolyzed to the amide 161 using a number of methods known in the literature (March, J., Advanced Org. Chem.; Reactions, Mechanisms, and Structure, p.
  • the ⁇ -phenethylamide of compound 63 can be prepared by treating 4-bromophenethylamine, 62, with ethyl formate. Treating intermediate 63 with polyphosphoric acicfand phosphorous pentoxide in a Bischler-Napieralski cyclodehyd ration produces the 7-bromo-3,4- dihydroisoquinoline 64. Sodium borohydride reduction of the hydrochloride salt of compound 64 in water produces the 7-bromo-1 , 2,3,4- tetrahydroisoquinoline 65.
  • Treating the amines of formula 68 with an isocyanate of formula 69 gives the urea of formula 70 as illustrated in Scheme 16.
  • the amine 68 can be functionalized with an acid chloride or acid to give the amide of formula 72, a sulfonyl chloride of formula 38 to give the sulfonamide 74, or a ketone of formula 154 and a reducing agent to give the amine of formula 155.
  • the resulting amines can be deprotected to give intermediates 71 , 73, 75 and 156 respectively.
  • the acid can then be coupled to amines of formula 147 to give compounds of formula 82. Subsequent deprotection of the amine generates compounds of formula 83.
  • compound of formula 80 can be deprotected to give intermediate 165.
  • the amine can then be coupled to acids of formula 11 to give compounds of formula 166. Subsequent deprotection of the amine generates intermediate 167. Hydrolysis of the ester transforms 167 into 168.
  • a catalyst such as tetrakis (triphenylphosphine) palladium(O) and potassium carbonate in toluene and aqueous ethanol
  • the boronic acid of formula 88 can be prepared by treating a suitably protected aniline 87 with t-butyllithium and trimethylborate at temperatures near ⁇ 78°C. Intermediate 88 can then be coupled to triflate 79 using conditions defined in Scheme 19 to give 89.
  • the aniline protecting group can then be selectively removed, and the resulting amine 90 treated with an isocyanate 69 and a suitable base to give the urea of formula 91. Deprotection of the amine transforms 91 to 92.
  • the amine of formula 90 can also be sulfonylated with a sulfonyl chloride in the presence of an acid scavenger to give compounds of formula 93.
  • phthalimides of formula 99 can be prepared from 4-aminopyridines 97 and phthalic anhydride 98 as described by Ciganek et al. U.S. Pat. Appl. 92/876542.
  • the pyridine ring of 99 can be reduced by a number of methods including hydrogenation in the presence of a platinum catalyst in a solvent such as methanolic HCl to give the piperidine ring of formula 157.
  • quaternization of the pyridine ring with benzyl bromide in ethanol leads to the quaternary salt 100.
  • the pyridine ring can then be reduced by a number of methods including hydrogenation in the presence of a platinum catalyst in glacial acetic acid or methanol to give 101.
  • Many other anhydrides are commercially available and one skilled in the art can apply such chemistry to these compounds.
  • hydride reducing agents such as sodium borohydride in methanol, or lithium borohydride in an aprotic solvent such as THF. Phthalimides may also be reduced to compounds of type 104 with zinc in acetic acid. Deprotection of the piperidine ring transforms 104 to 105.
  • Compounds of formula 104 can be treated with a base such as sodium hydride in appropriate solvents such as tetrahydrofuran, or metal alkoxides such as sodium methoxide in alcohol solvents such as methanol, followed by addition of an alkylating agent to give compounds of formula 106.
  • such compounds can be prepared by treating compounds of formula 104 with an alcohol in the presence of an acid such as hydrochloric or methanesulfonic at temperatures of about 0-100°C. Deprotection of the piperidine ring transforms 106 into 107.
  • Treating 110 with one equivalent of a base such as potassium tert- butoxide in a solvent such as THF, followed by addition of 111 and then by a second equivalent of base generates intermediate of formula 112 as illustrated in Scheme 22.
  • Conversion of 112 to 113 can be accomplished by a number of methods, including hydrogenation with a catalyst such as palladium in a mixture of ethanol and aqueous HCl.
  • the ester of 112 can be deprotected to give the intermediate acid 158.
  • the acid 158 can be coupled to amine 147 to give the amide of formula 159.
  • Conversion of 159 to 160 can be accomplished by a number of methods including hydrogenation with a catalyst such as platinum in methanolic HCl.
  • a differentially protected 3-aminopyrrolidine of formula 114 is selectively deprotected at the 3-amino position to give intermediate 115.
  • the amine can then be sulfonylated with a sulfonyl chloride 38 in the presence of an acid scavenger in a solvent such as dichloromethane to give 116.
  • the amine can be coupled to acid 35 as above to give 117. Deprotection of the pyrrolidine nitrogen of 116 and 117 generates compounds of formula 118 and 119 respectively.
  • isoindolines of formula 129 can be prepared from 126 by radical bromination using a suitable source of bromine radical such as N-bromosuccinimide and a suitable radical initiator such as AIBN (2,2 * - azobis(isobutyronitrile) in an inert solvent such as carbon tetrachloride to produce intermediates 127.
  • a suitable source of bromine radical such as N-bromosuccinimide
  • a suitable radical initiator such as AIBN (2,2 * - azobis(isobutyronitrile) in an inert solvent such as carbon tetrachloride to produce intermediates 127.
  • AIBN 2,2 * - azobis(isobutyronitrile)
  • an inert solvent such as carbon tetrachloride
  • an N-protected 4-hydroxypiperidine 142 can be treated with methanesulfonyl chloride in the presence of a base such as triethylamine in an inert solvent such as methylene chloride to give the intermediate mesylate of formula 143.
  • the mesylate can then be displaced with an imidazo[4,5-b]pyridine of formula 135 (for example, see Carpino et al., Biorg. & Med. Chem. Lett. 1994 4, pp 93-98 and references cited within) using a base such as sodium hydride in a solvent such as DMF or dioxane to give 144. Deprotection of the amine transforms 144 into 145.
  • Benzisoxazoles of formula 136 can be prepared as described by Villabolos et al., J. Med. Chem. 1994 37 pp 2721-2724.
  • the amine 136 can be coupled to acids of formula 35 as illustrated in Scheme 27 to give intermediates 137.
  • Deprotection of the piperidine amine gives 138.
  • amine 136 can be sulfonylated to give 139. Deprotection of the amine generates compounds of formula 140. SCHEME 28
  • Esters of formula 146 can be prepared by treating an acid of formula 5 with hydroxysuccinimide in the presence of a coupling agent such as EDC in an inert solvent such as methylene chloride as illustrated in Scheme 28. Treating the ester with an amino acid of formula 1 in a solvent such as DMF in the presence of a base such as diisopropylethylamine produces 11.
  • Compounds of formula 179 can be prepared by treating an indole of formula 178 with benzoyi chloride in pyridine as illustrated in Scheme 33. Subsequent heating of 179 with dibenzylamine and a catalyst such as palladium on carbon at temperatures at or near 210°C in a solvent such as diphenyl ether generates the intermediate of formula 180.
  • the indole nitrogen can be alkylated by treating 180 with cuprous bromide and bromobenzene in the presence of a base such as potassium carbonate in a suitable solvent such as N-methylpyrrolidine at reflux overnight to give intermediates of formula 181.
  • Quaternization of the pyridine nitrogen can be accomplished by treating 181 with benzyl bromide in a solvent such as benzene at refluxing temperatures to give intermediates of formula 192. Treating 192 with excess sodium borohydride in methanol generates the tetrahydropyridine 182. Hydrogenation of 182 with hydrogen in a solvent such as ethanol using a catalyst such as palladium produces the piperidine of formula 183.
  • Compound of formula 185 is prepared by refluxing a mixture of 184 in acetic anhydride for several hours.
  • the acid chloride can be prepared by treating 185 with either thionyl chloride or oxalyl chloride to give intermediates of formula 191.
  • Friedel-Crafts acylation of m-difluorobenzene with 191 in the presence of aluminum chloride as a catalyst produces 186.
  • Removal of the acetyl protecting group can be accomplished by heating 186 in a mixture of concentrated HCl and glacial acetic acid to give intermediate of formula 187.
  • the oxime 188 can then be prepared by refluxing 187 with triethylamine and hydroxylamine hydrochloride in ethanol for several hours. Refluxing the oxime in 50% NaOH produces the benzoisoxazole 189.
  • compounds of formula 193 can be prepared by treating anilines of formula 194 with N-protected piperidones of formula 22 in the presence of a hydride reducing agent such as sodium triacetoxyborohydride in a solvent such as acetic acid which contains an excess of sodium sulfate.
  • a hydride reducing agent such as sodium triacetoxyborohydride in a solvent such as acetic acid which contains an excess of sodium sulfate.
  • Treating 195 with sodium borohydride in a solvent such as ethanol generates the indole of formula 196. Deprotection of the amine transforms 196 into 197. -58-
  • Liquid secondary ion mass spectra were obtained on a Kratos ConcepMS high resolution spectrometer using cesium ion bombardment on sample dissolved in a 1 :5 mixture of dithioerythritol and dithiothreitol or in a thioglycerol matrix.
  • LSIMS Liquid secondary ion mass spectra
  • the mixture was diluted with ethyl acetate or other solvent as specified, and the resulting mixture washed twice with 1 N NaOH, twice with 1 N HCl (if the product is not basic), once with brine, dried over Na2S ⁇ 4, and concentrated giving the crude product which was purified as specified.
  • the carboxylic acid component could be used as the dicyclohexylamine salt in coupling to the primary amine or hydrochloride of the latter; in this case no triethylamine was employed.
  • the precipitated material was collected by filtration and washed with cold ethanol to give 25.0 g of a tan solid.
  • the crude material was partitioned between 1N NaOH and ethyl acetate.
  • the ethyl acetate layer was washed once with brine, dried over Na2S ⁇ 4 and concentrated.
  • the dinitrated tetrahydroisoquinoline was removed by crystallization from ether/hexanes.
  • the mother liquor was concentrated to give 2.19 g of 7-Nitro-1 ,2,3,4-tetrahydro- isoquinoline.
  • the ether layer was washed with water and brine, dried over MgS ⁇ 4, and evaporated.
  • the crude product was purified by silica gel chromatography using a gradient of 5%, 10%, and 20% methanol in chloroform to give 8.00 g of 7C as an oil.
  • Example 16 ylmethyl)-piperidin-1 -yl]-2-oxo-ethyl ⁇ -isobutyramide
  • the resulting solid was collected by filtration.
  • the N-Pyridin-4-ylmethyl-phthalamic acid was then cyclized, by heating 235 g (0.88 mol) to the melt stage for 15 min.
  • Example 18 ( ' R)-1'-f2-f2-Amino-2-methyl-propionylamino)-3-benzyloxy-propionyl1- [1.4'lbipiperidinyl-4'-carboxylic acid amide hydrochloride A. (1 -f1 -(R)-Benzyloxymethyl-2-(4'-carbamoyl- ⁇ ,4'1bipiperidinyl-1 '-vh-2- oxo-ethylcarbamoyl]-1 -methyl-ethyl ⁇ -carbamic acid tert-butyl ester
  • the mixture was diluted with chloroform and washed twice each with 10% hydrochloric acid, saturated aqueous sodium bicarbonate and brine.
  • the solution was dried over MgS ⁇ 4 and concentrated.
  • the product was purified by silica gel chromatography using a gradient of 75% ethyl acetate in hexane to 100% ethyl acetate to give 150 mg of 19A as a white solid.
  • A. 4-Phenyl-piperidine-4-carboxylic acid ethyl ester hydrochloride A mixture of 10.0 g (45 mmol) 4-cyano-4-phenylpiperidine hydrochloride, 10 g of sulfuric acid and 2.5 mL of water was heated at 150°C for 1 h. The mixture was allowed to cool to 110°C and 10 mL of ethanol was added. The ethanol was then distilled off. This ethanol addition/distillation was repeated four more times. Following the last addition, the mixture was heated to 125°C cooled to room temperature and poured onto ice. The mixture was basified with 10% NaOH and extracted twice with ether.
  • Example 41 1 -Amino-cyclopentanecarboxylic acid ⁇ 1 -(R)-benzyloxymethyl-2-oxo-2-[4-(2- oxo-2.3-dihydro-benzoimidazol-1-yl)-piperidin-1 -yl]-ethyl ⁇ -amide trifluoroacetate A. 1 -tert-Butoxycarbonylamino-cyclopentanecarboxylic acid
  • Example 43 ( • RVN- ⁇ 2-[2-('2-Amino-2-methyl-propionylaminoV3-benzyloxy-propiony ⁇ -2.3- dihydro-1 H-isoindol-5-yl ⁇ -benzamide trifluoroacetate A. 1.2-Bis-bromomethyl-4-nitro-benzene To 8.00 g (53.0 mmol) of 4-Nitro-o-xylene in 80 mL of carbon tetrachloride was added 18.8 g (106 mmol) of N-Bromosuccinimide followed by 100 mg (0.60 mmol) of 2,2'-azobis (isobutyronitrile) and the mixture was refluxed overnight.
  • Example 47 ⁇ RV2-Amino-N- ⁇ 1 -(1 H-indol-3-ylmethyh-2-oxo-2-[4- ⁇ 1 -phenyl-1 H-indol-3-yh- piperidin-1 -yl]-ethyl ⁇ -isobutyramide hydrochloride
  • [4-(1 H-lndol-3-yl)-4H-pyridin-1 -yl]-phenyl-methanone To a solution of 23.4 g (0.20 mol) of indole in 250 mL of pyridine was added 23.2 mL (0.20 mol) of benzoyi chloride with mechanical stirring and the mixture was stirred for 48 h.
  • Example 51 (R .-2-Amino-N-f2-f4- ⁇ 6-fluoro-benzofd1isoxazol-3-yh-piperidin-1 -yll-1 -(1 H- indol-3-ylmethyl)-2-oxo-ethyl]-isobutyramide hydrochloride
  • A. 1 -Acetyl-piperidine-4-carboxylic acid A mixture of 129.2 g (1.00 mmol) of isonipecotic acid and 400 mL of acetic anhydride was refluxed for 2.5 h. The mixture was allowed to cool to room temperature and stirred for 17 h. The precipitated solids were filtered, washed with diethyl ether and dried under vacuum to give 150.1 g of 51 A as a white solid.
  • A. 4-Phenyl-piperidine-1 ,4-dicarboxylic acid mono-tert-butyl ester To a suspension of 42.84 g (114 mmol) of 4-phenyl-4-piperidine carboxylic acid 4-methylbenzenesulfonate in 250 mL of dioxane and 50 mL of water was added 200 mL of 1 N NaOH, and the mixture was stirred until homogeneous. To the stirring mixture was added 27.3 g (125 mmol) of di-tert- butyldicarbonate over 15 min. Another 200 mL of 1N NaOH was added and the mixture was stirred until a pH of 10-11 was maintained.
  • Example 56 ( R ,-2-Amino-N-(1 -(1 H-indol-3-ylmethyl l-2-oxo-2-r4-.2-oxo-1.2-dihydro- imidazo[4.5-b]pyridin-3-yh-piperidin-1-yl]-ethyl ⁇ -isobutyramide hydrochloride A.
  • 66A was prepared by the same route illustrated in Example 56 using 4- chloro-3-nitro-pyridine and 4-amino-1 -benzylpiperidine as starting materials.
  • the 4-chloro-3-nitro-pyridine was prepared by adding 3.00 g (23.8 mmol) of 4- hydroxy-3-nitropyridine to 10 mL of phosphorous oxychloride and heating the mixture at 130°C for 3 h. The mixture was poured into ice water, neutralized with 2N NaOH and allowed to stand for 1 h. The mixture was extracted with ethyl acetate and the combined organics were washed with brine. The solution was dried and concentrated to give 2.92 g of 4-chloro-3-nitro-pyridine.
  • Example 70 (R ⁇ -2-Amino-N-f 1 -(1 H-indol-3-ylmethyh-2- ⁇ 4-indol-1 -yl-piperidin-1 -vh-2-oxo- ethyll-isobutyramide hydrochloride A. (1-Benzyl-piperidin-4-vh-phenyl-amine To a mixture of 10.9 g (57.6 mmol) of 1-benzyl-4-piperidone, 100.0 g
  • Example 74 R ,-2-Amino-N-f 2-( 1 H-indol-3-yh-1 -r6-.7-sulfamoyt-3.4-dihydro-1 H- isoquinoline-2-carbonyh-3.4-dihydro-1 H-isoquinoline-2- carbonyll-ethyh-isobutyramide hydrochloride
  • Example 78 (R Piperidine-4-carboxylic acid ⁇ 1 -naphthalen-1-ylmethyl-2-oxo-2-[4-.;2-oxo- 2.3-dihydro-benzoimidazol-1 -yl)-piperidin-1 -yl]- ethyl ⁇ -amide hydrochloride A.
  • 2-Trifluoroacetyl-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride can be prepared according to the method outlined by Pendleton et al., J. Pharmacol. Exp. Ther., 208 (1979) p24.
  • a mixture of 250 mg (0.76 mmol) of 2- Trifluoroacetyl-1 ,2,3,4-tetrahydro-isoquinoline-7-sulfonyl chloride, 86 mg (0.99 mmol) of morpholine and 0.3 mL of anhydrous pyridine in 10 mL of acetone was refluxed for 1 h. The mixture was concentrated and the residue dissolved in chloroform and washed once with water.
  • the orange oil was separated from the aqueous extracts and acidified with 10% acetic acid.
  • the aqueous portion was extracted three times with ethyl acetate and the combined organics were washed three times with water, once with brine, dried over MgS ⁇ 4 and concentrated to give 3.7 g of a yellow oil which was taken up in 200 mL of ether.
  • a white crystalline solid precipitated from solution and was collected by filtration to give 3.31 g of 80A.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Les composés de formule (I) sont des substances mimétiques peptidiques libérant l'hormone de croissance, utiles pour traiter et prévenir l'ostéoporose.
PCT/IB1995/000333 1995-05-08 1995-05-08 Dipeptides stimulant la liberation de l'hormone de croissance WO1996035713A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IB1995/000333 WO1996035713A1 (fr) 1995-05-08 1995-05-08 Dipeptides stimulant la liberation de l'hormone de croissance
CA002220055A CA2220055C (fr) 1995-05-08 1995-05-29 Dipeptides favorisant la secretion de l'hormone de croissance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1995/000333 WO1996035713A1 (fr) 1995-05-08 1995-05-08 Dipeptides stimulant la liberation de l'hormone de croissance
CA002220055A CA2220055C (fr) 1995-05-08 1995-05-29 Dipeptides favorisant la secretion de l'hormone de croissance

Publications (1)

Publication Number Publication Date
WO1996035713A1 true WO1996035713A1 (fr) 1996-11-14

Family

ID=25679791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1995/000333 WO1996035713A1 (fr) 1995-05-08 1995-05-08 Dipeptides stimulant la liberation de l'hormone de croissance

Country Status (1)

Country Link
WO (1) WO1996035713A1 (fr)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804578A (en) * 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5880125A (en) * 1996-03-21 1999-03-09 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
WO1999058501A1 (fr) * 1998-05-11 1999-11-18 Novo Nordisk A/S Composes possedant des proprietes de liberation d'hormone de croissance
EP1002802A1 (fr) * 1998-11-20 2000-05-24 Pfizer Products Inc. Dipéptides comme secretagogues d'hormone de croissance
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO2001087834A1 (fr) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
EP1159964A2 (fr) 2000-05-31 2001-12-05 Pfizer Products Inc. Compositions et methodes pour stimuler la motilité gastrointestinale
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
WO2002014277A1 (fr) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Composes de biphenylcarboxamidoisoindoline, procedes de preparation de ceux-ci et produits intermediaires destines a la synthese de ceux-ci
WO2002014276A1 (fr) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Composes a base de benzoylaminoisoindoline, leurs procedes de preparation et produits intermediaires utilises dans leur synthese
US6376509B2 (en) 2000-05-30 2002-04-23 Merck & Co., Inc. Melanocortin receptor agonists
US6468974B1 (en) 1998-08-14 2002-10-22 The Administrators Of The Tulane Educational Fund Compounds having growth hormone releasing activity
JP2003519222A (ja) * 1999-12-30 2003-06-17 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト 置換ピペリジン、これを含む医薬組成物及び製法
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
WO2004092166A2 (fr) 2003-04-15 2004-10-28 Merck & Co., Inc. Antagonistes des recepteurs cgrp
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
EP1506969A1 (fr) 1998-01-16 2005-02-16 Novo Nordisk A/S Composés présentant des propriétés de libération d'hormone de croissance
US6864250B1 (en) 1997-08-22 2005-03-08 Kaken Pharmaceutical Co., Ltd. N-acylated lipophilic amino acid derivatives
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
EP1363631A4 (fr) * 2001-03-02 2005-11-16 Bristol Myers Squibb Co Composes utiles comme modulateurs des recepteurs de la melanocortine et compositions pharmaceutiques renfermant ceux-ci
US7112600B1 (en) 1999-12-27 2006-09-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
WO2007098716A1 (fr) 2006-02-28 2007-09-07 Centro De Ingeniería Genética Y Biotecnología Composés analogues aux sécrétagogues peptidiques de l'hormone de croissance et préparations contenant ceux-ci
EP1930021A2 (fr) 1999-02-18 2008-06-11 Kaken Pharmaceutical Co., Ltd. Nouveaux dérivés d'amide en tant que secrétagogues d'hormone de croissance
US7396846B2 (en) 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
US7414057B2 (en) 2002-09-11 2008-08-19 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
US7511145B2 (en) 2003-08-01 2009-03-31 Genelabs Technologies, Inc. Bicyclic heteroaryl derivatives
EP2457893A1 (fr) 2004-06-18 2012-05-30 Tranzyme Pharma, Inc. Intermédiaires pour des modulateurs macrocycliques du récepteur de ghréline
WO2012131090A1 (fr) 2011-03-31 2012-10-04 Galderma Research & Development Procédé pour le traitement du xeroderma pigmentosum (épithéliomatose pigmentaire)
EP2644618A1 (fr) 2007-02-09 2013-10-02 Tranzyme Pharma, Inc. Intermédaires dans la synthese de modulateurs macrocycliques du récepteur de la ghréline
WO2013190520A2 (fr) 2012-06-22 2013-12-27 The General Hospital Corporation Agents de libération de gh dans le traitement d'une sténose vasculaire et d'états associés
EP2716659A1 (fr) * 2012-10-08 2014-04-09 Randox Laboratories Ltd. Dosages immunologiques pour mépéridine et métabolites
US8754085B2 (en) 2010-07-14 2014-06-17 Novartis Ag Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist
US8937069B2 (en) 2012-01-13 2015-01-20 Novartis Ag Substituted pyrrolo[2,3-B]pyrazine compounds and their use
CN106432232A (zh) * 2016-09-18 2017-02-22 苏州汉德创宏生化科技有限公司 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
WO2017075535A1 (fr) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Méthodes de traitement de troubles neurodégénératifs
US9771327B2 (en) 2013-03-13 2017-09-26 Flatley Discovery Lab, Llc Compounds and methods for the treatment of cystic fibrosis
CN107652265A (zh) * 2017-09-28 2018-02-02 沈阳药科大学 1‑(哌啶‑4‑基)‑2‑苯并咪唑酮类化合物及其应用
US10105416B2 (en) 2014-02-05 2018-10-23 The Regents Of The University Of California Methods of treating mild brain injury
CN116496270A (zh) * 2022-01-27 2023-07-28 四川大学华西医院 一类4-氨基哌啶衍生物及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013696A1 (fr) * 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro-piperidines et homologues favorisant la liberation de l'hormone de croissance
WO1995013069A1 (fr) * 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines et hexahydro-1h-azepines favorisant la liberation de l'hormone de croissance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013696A1 (fr) * 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro-piperidines et homologues favorisant la liberation de l'hormone de croissance
WO1995013069A1 (fr) * 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines et hexahydro-1h-azepines favorisant la liberation de l'hormone de croissance

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880125A (en) * 1996-03-21 1999-03-09 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
US5804578A (en) * 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
US7279573B2 (en) 1997-08-22 2007-10-09 Kaken Pharmaceutical Co., Ltd. Amide derivatives
US6864250B1 (en) 1997-08-22 2005-03-08 Kaken Pharmaceutical Co., Ltd. N-acylated lipophilic amino acid derivatives
US7064121B2 (en) 1997-08-22 2006-06-20 Kaken Pharmaceutical Co., Ltd. N-acylated lipophilic amino acid derivatives
EP1506969A1 (fr) 1998-01-16 2005-02-16 Novo Nordisk A/S Composés présentant des propriétés de libération d'hormone de croissance
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
CZ301276B6 (cs) * 1998-05-11 2009-12-30 Novo Nordisk A/S Piperidinový derivát vykazující schopnost uvolnování rustového hormonu
WO1999058501A1 (fr) * 1998-05-11 1999-11-18 Novo Nordisk A/S Composes possedant des proprietes de liberation d'hormone de croissance
RU2243215C2 (ru) * 1998-05-11 2004-12-27 Ново Нордиск А/С Производные пиперидинкарбоновых кислот, фармацевтические композиции, содержащие их, способ стимуляции секреции гормона роста
US7576062B2 (en) 1998-06-30 2009-08-18 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US7250399B2 (en) 1998-08-14 2007-07-31 The Administrators Of The Tulane Educational Fund Compounds having growth hormone releasing activity
US6468974B1 (en) 1998-08-14 2002-10-22 The Administrators Of The Tulane Educational Fund Compounds having growth hormone releasing activity
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6992097B2 (en) 1998-08-18 2006-01-31 Eli Lilly And Company Growth hormone secretagogues
EP1002802A1 (fr) * 1998-11-20 2000-05-24 Pfizer Products Inc. Dipéptides comme secretagogues d'hormone de croissance
EP1930021A2 (fr) 1999-02-18 2008-06-11 Kaken Pharmaceutical Co., Ltd. Nouveaux dérivés d'amide en tant que secrétagogues d'hormone de croissance
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US7112600B1 (en) 1999-12-27 2006-09-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US7285551B2 (en) 1999-12-27 2007-10-23 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
JP2003519222A (ja) * 1999-12-30 2003-06-17 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト 置換ピペリジン、これを含む医薬組成物及び製法
WO2001087834A1 (fr) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
US6376509B2 (en) 2000-05-30 2002-04-23 Merck & Co., Inc. Melanocortin receptor agonists
EP1159964A2 (fr) 2000-05-31 2001-12-05 Pfizer Products Inc. Compositions et methodes pour stimuler la motilité gastrointestinale
WO2002014277A1 (fr) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Composes de biphenylcarboxamidoisoindoline, procedes de preparation de ceux-ci et produits intermediaires destines a la synthese de ceux-ci
WO2002014276A1 (fr) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Composes a base de benzoylaminoisoindoline, leurs procedes de preparation et produits intermediaires utilises dans leur synthese
EP1363631A4 (fr) * 2001-03-02 2005-11-16 Bristol Myers Squibb Co Composes utiles comme modulateurs des recepteurs de la melanocortine et compositions pharmaceutiques renfermant ceux-ci
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
US7396846B2 (en) 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
US7414057B2 (en) 2002-09-11 2008-08-19 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
EP2039694A1 (fr) 2003-04-15 2009-03-25 Merck & Co., Inc. Antagonistes de récepteur CGRP
WO2004092166A2 (fr) 2003-04-15 2004-10-28 Merck & Co., Inc. Antagonistes des recepteurs cgrp
US7511145B2 (en) 2003-08-01 2009-03-31 Genelabs Technologies, Inc. Bicyclic heteroaryl derivatives
EP2457925A1 (fr) 2004-06-18 2012-05-30 Tranzyme Pharma, Inc. Procédé pour la préparation d'un modulateur macrocyclique du récepteur de ghréline et intermédiaires
EP2457893A1 (fr) 2004-06-18 2012-05-30 Tranzyme Pharma, Inc. Intermédiaires pour des modulateurs macrocycliques du récepteur de ghréline
WO2007098716A1 (fr) 2006-02-28 2007-09-07 Centro De Ingeniería Genética Y Biotecnología Composés analogues aux sécrétagogues peptidiques de l'hormone de croissance et préparations contenant ceux-ci
EP2644618A1 (fr) 2007-02-09 2013-10-02 Tranzyme Pharma, Inc. Intermédaires dans la synthese de modulateurs macrocycliques du récepteur de la ghréline
US9132127B2 (en) 2010-07-14 2015-09-15 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
US8754085B2 (en) 2010-07-14 2014-06-17 Novartis Ag Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist
WO2012131090A1 (fr) 2011-03-31 2012-10-04 Galderma Research & Development Procédé pour le traitement du xeroderma pigmentosum (épithéliomatose pigmentaire)
US9073932B2 (en) 2012-01-13 2015-07-07 Novartis Ag Substituted pyrrolo[2,3-B]pyrazines for the treatment of disorders and diseases
US8937069B2 (en) 2012-01-13 2015-01-20 Novartis Ag Substituted pyrrolo[2,3-B]pyrazine compounds and their use
WO2013190520A2 (fr) 2012-06-22 2013-12-27 The General Hospital Corporation Agents de libération de gh dans le traitement d'une sténose vasculaire et d'états associés
EP2716659A1 (fr) * 2012-10-08 2014-04-09 Randox Laboratories Ltd. Dosages immunologiques pour mépéridine et métabolites
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
US9771327B2 (en) 2013-03-13 2017-09-26 Flatley Discovery Lab, Llc Compounds and methods for the treatment of cystic fibrosis
US10105416B2 (en) 2014-02-05 2018-10-23 The Regents Of The University Of California Methods of treating mild brain injury
US10617740B2 (en) 2014-02-05 2020-04-14 The Regents Of The University Of California Methods of treating mild brain injury
US11241483B2 (en) 2014-02-05 2022-02-08 The Regents Of The University Of California Methods of treating mild brain injury
WO2017075535A1 (fr) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Méthodes de traitement de troubles neurodégénératifs
CN106432232A (zh) * 2016-09-18 2017-02-22 苏州汉德创宏生化科技有限公司 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法
CN107652265A (zh) * 2017-09-28 2018-02-02 沈阳药科大学 1‑(哌啶‑4‑基)‑2‑苯并咪唑酮类化合物及其应用
CN116496270A (zh) * 2022-01-27 2023-07-28 四川大学华西医院 一类4-氨基哌啶衍生物及其制备方法和用途

Similar Documents

Publication Publication Date Title
US5936089A (en) Dipeptides which promote release of growth hormone
WO1996035713A1 (fr) Dipeptides stimulant la liberation de l'hormone de croissance
EP1372653B1 (fr) Derives de piperidine acyles utilises comme agonistes du recepteur de la melanocortine-4
AU716934B2 (en) Growth-hormone secretagogues
US5767118A (en) 4-Heterocyclic peperidines promote release of growth hormone
EP0615977B1 (fr) Spiro piperidines et ses homologues favorisants la libération de l'hormone de croissance
US5783582A (en) Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone
US5804578A (en) Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
AU1172995A (en) Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
BRPI0611922A2 (pt) compostos orgánicos
WO2001000657A2 (fr) Nouveaux peptidomimetiques d'indole, antagonistes du recepteur de la thrombine
US5731317A (en) Bridged piperidines promote release of growth hormone
IE902238A1 (en) Tetrapeptide type-b cck receptor ligands
NO318080B1 (no) 4,4- og 3,3-disubstiterte piperidin-forbindelser med veksthormonfrigjorende egenskaper,farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene eller preparatene til fremstilling av medikamenter
US5880125A (en) 4-spiroindoline piperidines promote release of growth hormone
WO1997036873A1 (fr) Piperidines, pyrrolidines et hexahydro-1h-azepines declenchant la liberation de l'hormone de croissance
US5656606A (en) Camphor compounds promote release of growth hormone
WO1998025897A1 (fr) Piperidines, pyrrolidines et hexahydro-1h azepines favorisent la liberation de l'hormone de croissance
AU4167100A (en) Novel amide derivatives as growth hormone secretagogues
US7514409B2 (en) VLA-4 antagonists
CA2576647C (fr) Antagonistes de vla-4

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA FI JP MX US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA